The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.
Sottotetti F, Ferraris E, Tagliaferri B, Palumbo R, Quaquarini E, Teragni C, Balletti E, Leli C, Premoli A, Mollica L, Puglisi S, Sardi S, Malovini A, Pedrazzoli P, Bernardo A.
Sottotetti F, et al. Among authors: leli c.
Drugs Context. 2022 Sep 5;11:2022-1-3. doi: 10.7573/dic.2022-1-3. eCollection 2022.
Drugs Context. 2022.
PMID: 36118250
Free PMC article.